TABLE 4.
No. of C at rs3760091 | No. of A at rs750155 | No. of G at rs9282861 | |||||||
Hormone | oCEE | tE2 | Placebo | oCEE | tE2 | Placebo | oCEE | tE2 | Placebo |
E1 | 0.43 | 0.32 | 0.65 | 0.09 | 0.77 | 0.44 | 0.19 | 0.97 | 0.41 |
E1S | 0.26 | 0.56 | 0.43 | 0.004 | 0.28 | 0.33 | 0.13 | 0.61 | 0.81 |
E1S/E1 | 0.24 | 0.75 | 0.74 | 0.17 | 0.15 | 0.21 | 0.47 | 0.42 | 0.74 |
E2 | 0.73 | 0.45 | 0.63 | 0.28 | 0.46 | 0.90 | 0.31 | 0.79 | 0.62 |
E2S | 0.18 | 0.53 | 0.53 | 0.017 | 0.27 | 0.23 | 0.29 | 0.16 | 0.42 |
E2S/E2 | 0.044 | 0.54 | 0.21 | 0.33 | 0.44 | 0.06 | 0.86 | 0.97 | 0.54 |
Statistically significant associations (<0.05) are in bold. E1, estrone; E1S, estrone sulfate; E2, 17β-estradiol; E2S, estradiol sulfate; oCEE, oral conjugated equine estrogen; SNP, single nucleotide polymorphism; t, transdermal.